GSK今日宣布，欧洲药品管理局（EMA）已接受靶向B细胞成熟抗原（BCMA）的抗体偶联药物（ADC）Blenrep（belantamab mafodotin）与硼替佐米加地塞米松（BorDex ...

该试验评估了Blenrep联合硼替佐米和地塞米松(BorDex)作为复发或难治性多发性骨髓瘤的二线或更晚期治疗的效果。试验达到了总生存期(OS)的关键次要 ...

China’s National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) for GSK's Blenrep (belantamab mafodotin) combined ...

GSK plc announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus ...

The trial showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) for belantamab mafodotin along with BorDex as against daratumumab plus BorDex ...

GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab mafodotin) along with bortezomib and dexamethasone (BorDex ...

GSK plc announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) in combination with bortezomib plus ...

The clinical trial met the key secondary endpoint of overall survival (OS), demonstrating that the combination of belantamab mafodotin with BorDex significantly diminished the risk of mortality in ...

In June, GSK released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial of Blenrep in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care ...

GSK said it had seen “statistically significant and clinically meaningful” trial results for Blenrep when used with another established treatment called BorDex to treat relapsed or refractory ...

The DREAMM-7 phase III clinical trial is a multicentre, open-label, randomised trial evaluating the efficacy and safety of belantamab mafodotin in combination with BorDex compared to a combination ...

Follow-up for OS continues. The DREAMM-7 trial is evaluating belantamab mafodotin combined with BorDex versus daratumumab plus BorDex, while the DREAMM-8 trial is evaluating belantamab mafodotin ...